Omnicell Stock Earnings Reports

Omnicell reported a strong start to FY2026 with Q1 revenue of $310M (up 15% YoY), non-GAAP EBITDA of $45M and non-GAAP EPS of $0.55, outperforming prior guidance. Product revenue grew 20% to $175M and service revenue rose 8% to $135M. Gross margin expanded to ~46% (driven by favorable product mix in connected devices and lapping 2025 software upgrade investments). Cash was $239M at quarter end after repaying $175M of debt and share repurchases; free cash flow was $39M. Management highlighted continued strength in recurring revenue, an improving and active competitive pipeline, and growing demand for enterprise platform solutions. They formally launched Titan XT (next‑generation automated dispensing hardware) and OmniSphere (cloud-native medication management platform), with initial Titan XT hardware shipments planned for H2 2026 and phased OmniSphere rollouts beginning in H1 2027. Management expects modest Titan XT revenue in 2026 and reiterated a total replacement opportunity in excess of $2.5B while noting multi-quarter to multi-year health system purchasing cycles. Q2 2026 guidance: revenue $307M–$313M; non-GAAP EBITDA $37M–$42M; non-GAAP EPS $0.40–$0.48. Full-year 2026 guidance: revenue $1.215B–$1.255B; product bookings $510M–$560M; year-end ARR $680M–$700M; non-GAAP EBITDA raised to $153M–$168M and non-GAAP EPS raised to $1.80–$2.00 (includes estimated $12M of tariff-related costs). Management emphasized disciplined cost control, continued R&D/investment in AI-enabled automation and services, and increasing competitive conversion opportunities as incumbents face reliability/service challenges.